[1]
Feldmann H, Sprecher A, Geisbert TW. Ebola. The New England journal of medicine. 2020 May 7:382(19):1832-1842. doi: 10.1056/NEJMra1901594. Epub
[PubMed PMID: 32441897]
[2]
Dixon MG, Schafer IJ, Centers for Disease Control and Prevention (CDC). Ebola viral disease outbreak--West Africa, 2014. MMWR. Morbidity and mortality weekly report. 2014 Jun 27:63(25):548-51
[PubMed PMID: 24964881]
[3]
Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH. Ebola virus disease. Nature reviews. Disease primers. 2020 Feb 20:6(1):13. doi: 10.1038/s41572-020-0147-3. Epub 2020 Feb 20
[PubMed PMID: 32080199]
[4]
Khan S, Muhammad, Rauf A, Khan A, Rizwan M, Patel S, Khan H, Mahasneh AM, Mubarak MS. Comprehensive Review on Ebola (EBOV) Virus: Future Prospects. Infectious disorders drug targets. 2018:18(2):96-104. doi: 10.2174/1871526517666170817100828. Epub
[PubMed PMID: 28820067]
[5]
Emanuel J, Marzi A, Feldmann H. Filoviruses: Ecology, Molecular Biology, and Evolution. Advances in virus research. 2018:100():189-221. doi: 10.1016/bs.aivir.2017.12.002. Epub 2018 Feb 1
[PubMed PMID: 29551136]
Level 3 (low-level) evidence
[6]
Hayman DT, Yu M, Crameri G, Wang LF, Suu-Ire R, Wood JL, Cunningham AA. Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerging infectious diseases. 2012 Jul:18(7):1207-9. doi: 10.3201/eid1807.111654. Epub
[PubMed PMID: 22710257]
[7]
Letafati A, Salahi Ardekani O, Karami H, Soleimani M. Ebola virus disease: A narrative review. Microbial pathogenesis. 2023 Aug:181():106213. doi: 10.1016/j.micpath.2023.106213. Epub 2023 Jun 23
[PubMed PMID: 37355146]
Level 3 (low-level) evidence
[8]
Lacroix A, Mbala Kingebeni P, Ndimbo Kumugo SP, Lempu G, Butel C, Serrano L, Vidal N, Thaurignac G, Esteban A, Mukadi Bamuleka D, Likofata J, Delaporte E, Muyembe Tamfum JJ, Ayouba A, Peeters M, Ahuka Mundeke S. Investigating the Circulation of Ebola Viruses in Bats during the Ebola Virus Disease Outbreaks in the Equateur and North Kivu Provinces of the Democratic Republic of Congo from 2018. Pathogens (Basel, Switzerland). 2021 May 4:10(5):. doi: 10.3390/pathogens10050557. Epub 2021 May 4
[PubMed PMID: 34064424]
[9]
Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, Juste J, Quetglas J, Savji N, de la Cruz Martínez M, Herrera JE, Pizarro M, Hutchison SK, Echevarría JE, Lipkin WI, Tenorio A. Discovery of an ebolavirus-like filovirus in europe. PLoS pathogens. 2011 Oct:7(10):e1002304. doi: 10.1371/journal.ppat.1002304. Epub 2011 Oct 20
[PubMed PMID: 22039362]
[10]
Broadhurst MJ, Brooks TJ, Pollock NR. Diagnosis of Ebola Virus Disease: Past, Present, and Future. Clinical microbiology reviews. 2016 Oct:29(4):773-93. doi: 10.1128/CMR.00003-16. Epub
[PubMed PMID: 27413095]
[11]
Tomori O, Kolawole MO. Ebola virus disease: current vaccine solutions. Current opinion in immunology. 2021 Aug:71():27-33. doi: 10.1016/j.coi.2021.03.008. Epub 2021 Apr 17
[PubMed PMID: 33873076]
Level 3 (low-level) evidence
[12]
Barbiero VK. Ebola: A Hyperinflated Emergency. Global health, science and practice. 2020 Jun 30:8(2):178-182. doi: 10.9745/GHSP-D-19-00422. Epub 2020 Jun 30
[PubMed PMID: 32430358]
[13]
Baudel H, De Nys H, Mpoudi Ngole E, Peeters M, Desclaux A. Understanding Ebola virus and other zoonotic transmission risks through human-bat contacts: Exploratory study on knowledge, attitudes and practices in Southern Cameroon. Zoonoses and public health. 2019 May:66(3):288-295. doi: 10.1111/zph.12563. Epub 2019 Jan 24
[PubMed PMID: 30677236]
Level 3 (low-level) evidence
[14]
Nkoghe D, Formenty P, Leroy EM, Nnegue S, Edou SY, Ba JI, Allarangar Y, Cabore J, Bachy C, Andraghetti R, de Benoist AC, Galanis E, Rose A, Bausch D, Reynolds M, Rollin P, Choueibou C, Shongo R, Gergonne B, Koné LM, Yada A, Roth C, Mve MT. [Multiple Ebola virus haemorrhagic fever outbreaks in Gabon, from October 2001 to April 2002]. Bulletin de la Societe de pathologie exotique (1990). 2005 Sep:98(3):224-9
[PubMed PMID: 16267965]
[15]
Bisimwa P, Biamba C, Aborode AT, Cakwira H, Akilimali A. Ebola virus disease outbreak in the Democratic Republic of the Congo: A mini-review. Annals of medicine and surgery (2012). 2022 Aug:80():104213. doi: 10.1016/j.amsu.2022.104213. Epub 2022 Jul 20
[PubMed PMID: 35875058]
[16]
Cenciarelli O, Gabbarini V, Pietropaoli S, Malizia A, Tamburrini A, Ludovici GM, Carestia M, Di Giovanni D, Sassolini A, Palombi L, Bellecci C, Gaudio P. Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013-2015. Virus research. 2015 Dec 2:210():318-26. doi: 10.1016/j.virusres.2015.09.002. Epub 2015 Sep 8
[PubMed PMID: 26359111]
[17]
Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Ströher U. Ebola Virus Persistence in Semen of Male Survivors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Jun 15:62(12):1552-1555. doi: 10.1093/cid/ciw202. Epub 2016 Apr 3
[PubMed PMID: 27045122]
[18]
Fischer WA 2nd, Wohl DA. Confronting Ebola as a Sexually Transmitted Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 May 15:62(10):1272-6. doi: 10.1093/cid/ciw123. Epub 2016 Mar 1
[PubMed PMID: 26936667]
[19]
Maxmen A. Ebola outbreak declared an international public-health emergency. Nature. 2019 Jul 17:():. doi: 10.1038/d41586-019-02221-3. Epub 2019 Jul 17
[PubMed PMID: 32669721]
[20]
Curran KG, Gibson JJ, Marke D, Caulker V, Bomeh J, Redd JT, Bunga S, Brunkard J, Kilmarx PH. Cluster of Ebola Virus Disease Linked to a Single Funeral - Moyamba District, Sierra Leone, 2014. MMWR. Morbidity and mortality weekly report. 2016 Mar 4:65(8):202-5. doi: 10.15585/mmwr.mm6508a2. Epub 2016 Mar 4
[PubMed PMID: 26938950]
[21]
Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM. The Pathogenesis of Ebola Virus Disease. Annual review of pathology. 2017 Jan 24:12():387-418. doi: 10.1146/annurev-pathol-052016-100506. Epub
[PubMed PMID: 27959626]
[22]
Zawilińska B, Kosz-Vnenchak M. General introduction into the Ebola virus biology and disease. Folia medica Cracoviensia. 2014:54(3):57-65
[PubMed PMID: 25694096]
[23]
Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011 Jul:17(7):964-76. doi: 10.1111/j.1469-0691.2011.03535.x. Epub
[PubMed PMID: 21722250]
Level 3 (low-level) evidence
[24]
Marshall Lyon G, Mehta AK, Ribner BS. Clinical Management of Patients with Ebola Virus Disease in High-Resource Settings. Current topics in microbiology and immunology. 2017:411():115-137. doi: 10.1007/82_2017_19. Epub
[PubMed PMID: 28601946]
[25]
Lamontagne F, Fowler RA, Adhikari NK, Murthy S, Brett-Major DM, Jacobs M, Uyeki TM, Vallenas C, Norris SL, Fischer WA 2nd, Fletcher TE, Levine AC, Reed P, Bausch DG, Gove S, Hall A, Shepherd S, Siemieniuk RA, Lamah MC, Kamara R, Nakyeyune P, Soka MJ, Edwin A, Hazzan AA, Jacob ST, Elkarsany MM, Adachi T, Benhadj L, Clément C, Crozier I, Garcia A, Hoffman SJ, Guyatt GH. Evidence-based guidelines for supportive care of patients with Ebola virus disease. Lancet (London, England). 2018 Feb 17:391(10121):700-708. doi: 10.1016/S0140-6736(17)31795-6. Epub 2017 Oct 17
[PubMed PMID: 29054555]
Level 1 (high-level) evidence
[26]
Mérens A, Bigaillon C, Delaune D. Ebola virus disease: Biological and diagnostic evolution from 2014 to 2017. Medecine et maladies infectieuses. 2018 Mar:48(2):83-94. doi: 10.1016/j.medmal.2017.11.002. Epub 2017 Dec 8
[PubMed PMID: 29224715]
[27]
Southern TR, Racsa LD, Albariño CG, Fey PD, Hinrichs SH, Murphy CN, Herrera VL, Sambol AR, Hill CE, Ryan EL, Kraft CS, Campbell S, Sealy TK, Schuh A, Ritchie JC, Lyon GM 3rd, Mehta AK, Varkey JB, Ribner BS, Brantly KP, Ströher U, Iwen PC, Burd EM. Comparison of FilmArray and Quantitative Real-Time Reverse Transcriptase PCR for Detection of Zaire Ebolavirus from Contrived and Clinical Specimens. Journal of clinical microbiology. 2015 Sep:53(9):2956-60. doi: 10.1128/JCM.01317-15. Epub 2015 Jul 8
[PubMed PMID: 26157148]
[28]
Muzembo BA, Kitahara K, Ohno A, Ntontolo NP, Ngatu NR, Okamoto K, Miyoshi SI. Rapid diagnostic tests versus RT-PCR for Ebola virus infections: a systematic review and meta-analysis. Bulletin of the World Health Organization. 2022 Jul 1:100(7):447-458. doi: 10.2471/BLT.21.287496. Epub 2022 Jun 1
[PubMed PMID: 35813519]
Level 1 (high-level) evidence
[29]
Moran Z, Rodriguez W, Ahmadou D, Soropogui B, Magassouba NF, Kelly-Cirino C, Ben Amor Y. Comparative performance study of three Ebola rapid diagnostic tests in Guinea. BMC infectious diseases. 2020 Sep 15:20(1):670. doi: 10.1186/s12879-020-05339-2. Epub 2020 Sep 15
[PubMed PMID: 32933492]
Level 2 (mid-level) evidence
[30]
Coarsey CT, Esiobu N, Narayanan R, Pavlovic M, Shafiee H, Asghar W. Strategies in Ebola virus disease (EVD) diagnostics at the point of care. Critical reviews in microbiology. 2017 Nov:43(6):779-798. doi: 10.1080/1040841X.2017.1313814. Epub 2017 Apr 25
[PubMed PMID: 28440096]
[31]
Vogl TJ, Martin S, Brodt HR, Keppler O, Zacharowski K, Wolf T. The Frankfurt Ebola patient. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2015 Sep:187(9):771-6. doi: 10.1055/s-0035-1553130. Epub 2015 Jun 19
[PubMed PMID: 26090732]
[32]
Althaus CL. Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa. PLoS currents. 2014 Sep 2:6():. pii: ecurrents.outbreaks.91afb5e0f279e7f29e7056095255b288. doi: 10.1371/currents.outbreaks.91afb5e0f279e7f29e7056095255b288. Epub 2014 Sep 2
[PubMed PMID: 25642364]
[33]
Biedron C, Lyman M, Stuckey MJ, Homsy J, Lamorde M, Luvsansharav UO, Wilson K, Gomes D, Omuut W, Okware S, Semanda JN, Kiggundu R, Bulwadda D, Brown V, Nelson LJ, Driwale A, Fagan R, Park BJ, Smith RM. Evaluation of Infection Prevention and Control Readiness at Frontline Health Care Facilities in High-Risk Districts Bordering Ebola Virus Disease-Affected Areas in the Democratic Republic of the Congo - Uganda, 2018. MMWR. Morbidity and mortality weekly report. 2019 Oct 4:68(39):851-854. doi: 10.15585/mmwr.mm6839a4. Epub 2019 Oct 4
[PubMed PMID: 31581162]
[34]
Bell BP, Damon IK, Jernigan DB, Kenyon TA, Nichol ST, O'Connor JP, Tappero JW. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic. MMWR supplements. 2016 Jul 8:65(3):4-11. doi: 10.15585/mmwr.su6503a2. Epub 2016 Jul 8
[PubMed PMID: 27389903]
Level 3 (low-level) evidence
[35]
Cummings KJ, Choi MJ, Esswein EJ, de Perio MA, Harney JM, Chung WM, Lakey DL, Liddell AM, Rollin PE. Addressing Infection Prevention and Control in the First U.S. Community Hospital to Care for Patients With Ebola Virus Disease: Context for National Recommendations and Future Strategies. Annals of internal medicine. 2016:165(1):41-49. doi: 10.7326/M15-2944. Epub 2016 May 10
[PubMed PMID: 27159355]
[36]
Verbeek JH, Rajamaki B, Ijaz S, Sauni R, Toomey E, Blackwood B, Tikka C, Ruotsalainen JH, Kilinc Balci FS. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff. The Cochrane database of systematic reviews. 2020 May 15:5(5):CD011621. doi: 10.1002/14651858.CD011621.pub5. Epub 2020 May 15
[PubMed PMID: 32412096]
Level 1 (high-level) evidence
[37]
Shenoy ES, Weber DJ. Lessons learned in infection prevention for Ebola virus disease and the coronavirus disease 2019 (COVID-19) pandemic-Principles underlying prevention. Infection control and hospital epidemiology. 2021 Apr:42(4):457-460. doi: 10.1017/ice.2020.1427. Epub 2021 Jan 11
[PubMed PMID: 33427132]
[38]
Bogoch II, Creatore MI, Cetron MS, Brownstein JS, Pesik N, Miniota J, Tam T, Hu W, Nicolucci A, Ahmed S, Yoon JW, Berry I, Hay SI, Anema A, Tatem AJ, MacFadden D, German M, Khan K. Assessment of the potential for international dissemination of Ebola virus via commercial air travel during the 2014 west African outbreak. Lancet (London, England). 2015 Jan 3:385(9962):29-35. doi: 10.1016/S0140-6736(14)61828-6. Epub 2014 Oct 21
[PubMed PMID: 25458732]
[39]
Nuzzo JB, Cicero AJ, Waldhorn R, Inglesby TV. Travel bans will increase the damage wrought by ebola. Biosecurity and bioterrorism : biodefense strategy, practice, and science. 2014 Nov-Dec:12(6):306-9. doi: 10.1089/bsp.2014.1030. Epub
[PubMed PMID: 25397355]
[40]
Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, Heisenberg-Mansaray S, Tamba E, Sheriff A, Conteh S, Smith T, Tobin S, Brooks T, Houlihan C, Cummings R, Fletcher T. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. The Lancet. Infectious diseases. 2015 Nov:15(11):1292-9. doi: 10.1016/S1473-3099(15)00144-9. Epub 2015 Aug 10
[PubMed PMID: 26271406]
[41]
Kaplon H, Reichert JM. Antibodies to watch in 2021. mAbs. 2021 Jan-Dec:13(1):1860476. doi: 10.1080/19420862.2020.1860476. Epub
[PubMed PMID: 33459118]
[42]
Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M. Ebanga™: The most recent FDA-approved drug for treating Ebola. Frontiers in pharmacology. 2023:14():1083429. doi: 10.3389/fphar.2023.1083429. Epub 2023 Mar 8
[PubMed PMID: 36969842]
[44]
Wong G. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine. mBio. 2019 Jul 16:10(4):. doi: 10.1128/mBio.01597-19. Epub 2019 Jul 16
[PubMed PMID: 31311887]
[45]
PREVAC Study Team, Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D'Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai M, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. Randomized Trial of Vaccines for Zaire Ebola Virus Disease. The New England journal of medicine. 2022 Dec 29:387(26):2411-2424. doi: 10.1056/NEJMoa2200072. Epub 2022 Dec 14
[PubMed PMID: 36516078]
Level 1 (high-level) evidence
[46]
PREVAIL II Writing Group, Multi-National PREVAIL II Study Team, Davey RT Jr, Dodd L, Proschan MA, Neaton J, Neuhaus Nordwall J, Koopmeiners JS, Beigel J, Tierney J, Lane HC, Fauci AS, Massaquoi MBF, Sahr F, Malvy D. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. The New England journal of medicine. 2016 Oct 13:375(15):1448-1456
[PubMed PMID: 27732819]
Level 1 (high-level) evidence
[47]
Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, PALM Consortium Study Team. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England journal of medicine. 2019 Dec 12:381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27
[PubMed PMID: 31774950]
Level 1 (high-level) evidence
[48]
Pardo J, Shukla AM, Chamarthi G, Gupte A. The journey of remdesivir: from Ebola to COVID-19. Drugs in context. 2020:9():. doi: 10.7573/dic.2020-4-14. Epub 2020 May 22
[PubMed PMID: 32547625]
[49]
Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clinical microbiology reviews. 2020 Dec 16:34(1):. doi: 10.1128/CMR.00162-20. Epub 2020 Oct 14
[PubMed PMID: 33055231]
[50]
Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014 Oct 2:514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29
[PubMed PMID: 25171469]
Level 2 (mid-level) evidence
[51]
Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. Journal of global infectious diseases. 2017 Oct-Dec:9(4):151-156. doi: 10.4103/jgid.jgid_66_17. Epub
[PubMed PMID: 29302150]